Tear film lipid layer and ocular surface (TFLL)

The tear film lipid layer (TFLL) and the ocular surface represent a complex functional unit essential for maintaining ocular health and visual clarity. The TFLL, primarily secreted by the meibomian glands, forms the outermost interface of the tear film, where it serves to reduce surface tension and prevent the evaporation of the underlying aqueous layer (Source: StatPearls, 'Dry Eye Disease'). The ocular surface encompasses the cornea, conjunctiva, and the tear film, working together to provide a smooth refractive surface and a protective barrier against environmental insults and pathogens (Source: TFOS DEWS II Report). Dysfunction within this system, such as meibomian gland dysfunction (MGD) or aqueous deficiency, leads to dry eye disease (DED), characterized by tear film instability, hyperosmolarity, and inflammation (Source: Mayo Clinic). Therapeutic interventions target this system through various mechanisms, including the application of lipid-based lubricants like perfluorohexyloctane to stabilize the TFLL, anti-inflammatory agents like cyclosporine to treat the ocular surface, and secretagogues like varenicline to enhance natural tear production (Source: FDA, 'Miebo Label'; PubMed). While not a single molecular target, the ocular surface system is the primary focus of ophthalmic pharmacology for ocular surface disorders.

Other names

Precorneal tear filmOcular surface systemTear filmLachrymal film

Reduction of tear evaporation through lipid supplementation, stabilization of the tear film interface, reduction of ocular surface inflammation, and stimulation of aqueous and mucin secretion.